Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · see citing works

Bevacizumab in Combination with Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955 · see citing works

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279 · see citing works

Panitumumab–FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer

Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · see citing works

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor <i>KRAS</i> and <i>BRAF</i> Mutation Status

Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882 · see citing works

FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First-Line Treatment for Patients with Metastatic Colorectal Cancer (FIRE-3): A Randomised, Open-Label, Phase 3 Trial

Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740 · see citing works

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

Schmoll, H., Cutsem, E. V., Stein, A., Valentini, V., Glimelius, B. L. G., Haustermans, K. M., Nordlinger, B., van de Velde, C. J., Balmañà, J., Reguła, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,509 · see citing works

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients with Metastatic Colorectal Cancer Previously Treated with an Oxaliplatin-Based Regimen

Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402 · see citing works

Continuation of Bevacizumab after First Progression in Metastatic Colorectal Cancer (ML18147): A Randomised Phase 3 Trial

Bennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166 · see citing works

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausová, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1193 · Cited by 940 · see citing works

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

Bokemeyer, C., Bondarenko, I., Hartmann, J. T., de Braud, F., Schuch, G., Zubel, A., Celik, I., Schlichting, M., & Koralewski, P. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq632 · Cited by 775 · see citing works

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.

Viloria‐Petit, A., Crombet, T., Jothy, S., Hicklin, D. J., Böhlen, P., Schlaeppi, J.-M., Rak, J. W., & Kerbel, R. S. (2001) · PubMed · Cited by 558 · see citing works

CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).

Venook, A. P., Niedzwiecki, D., Lenz, H., Innocenti, F., Mahoney, M. R., O’Neil, B. H., Shaw, J. E., Polite, B. N., Höchster, H. S., Atkins, J. N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.18_suppl.lba3 · Cited by 428 · see citing works

Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy

Ciardiello, F., Bianco, R., Caputo, R., Caputo, R., Damiano, V., Troiani, T., Melisi, D., De Vita, F., De Placido, S., Bianco, A. R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1100-03 · Cited by 347 · see citing works

Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer

Peeters, M., Price, T. J., Cervantes, A. M. R., Sobrero, A. F., Ducreux, M. P., Hotko, Y., André, T., Chan, E. W., Lordick, F., Punt, C. J. A., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt523 · Cited by 215 · see citing works

Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC).

Koopman, M., Simkens, L. H. J., May, A. M., Mol, L., van Tinteren, H., Punt, C. J. A., & on behalf of the CAIRO3 Study Group (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.3_suppl.lba388 · Cited by 45 · see citing works

SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).

Hecht, J. R., Cohn, A. L., Dakhil, S. R., Saleh, M. N., Piperdi, B., Cline-Burkhardt, V. J. M., Tian, Y., & Go, W. Y. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.4_suppl.454 · Cited by 21 · see citing works

SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).

Cohn, A. L., Hecht, J. R., Dakhil, S. R., Saleh, M. N., Piperdi, B., Cline-Burkhardt, V. J. M., Tian, Y., & Go, W. Y. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3616 · Cited by 20 · see citing works

Cetuximab or bevacizumab in metastatic colorectal cancer?

Sclafani, F., & Cunningham, D. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70360-2 · Cited by 12 · see citing works

Maintenance Strategy with Fluoropyrimidines (Fp) Plus Bevacizumab (Bev), Bev Alone or No Treatment, Following a 24-Week First-Line Induction with Fp, Oxaliplatin (Ox) and Bev for Patients with Metastatic Colorectal Cancer: Mature Data and Subgroup Analysis of the Aio Krk 0207 Phase III Study

Hegewisch-Becker, S., Graeven, U., Lerchenmuller, C. A., Killing, B., Depenbusch, R., Steffens, C.-C., Al‐Batran, S., Lange, T., Dietrich, G., Stoehlmacher, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu333.2 · Cited by 10 · see citing works

Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D. A., Farkas, L. M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,709 · see citing works

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

Venook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Fruth, B., Meyerhardt, J. A., Schrag, D., Greene, C., O'Neil, B. H., Atkins, J. N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7105 · Cited by 898 · see citing works

Treatment sequencing in metastatic colorectal cancer

Modest, D. P., Pant, S., & Bianchi, A. S. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.019 · Cited by 328 · see citing works

Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With <i>RAS</i> Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial

Watanabe, J., Muro, K., Shitara, K., Yamazaki, K., Shiozawa, M., Ohori, H., Takashima, A., Yokota, M., Makiyama, A., Akazawa, N., et al. (2023) · JAMA · doi:10.1001/jama.2023.4428 · Cited by 280 · see citing works

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies

Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental &amp; Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246 · see citing works

S3-Leitlinie – Kolorektales Karzinom

Schmiegel, W., Buchberger, B., Follmann, M., Graeven, U., Heinemann, V., Langer, T. G., Nothacker, M., Porschen, R., Rödel, C. M., Rösch, T., et al. (2017) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0043-121106 · Cited by 242 · see citing works

FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

Heinemann, V., von Weikersthal, L. F., Decker, T. W., Kiani, A., Kaiser, F., Al-Batran, S.-E., Heintges, T., Lerchenmueller, C., Kahl, C., Seipelt, G., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01140-9 · Cited by 173 · see citing works

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study

Stintzing, S., Miller‐Phillips, L., Modest, D. P., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al-Batran, S.-E., Heintges, T., Kahl, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.03.023 · Cited by 136 · see citing works

Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma

Rivera, F., Karthaus, M., Hecht, J. R., Sevilla, I., Forget, F., Fasola, G., Canon, J.-L. R., Guan, X., Demonty, G., & Schwartzberg, L. S. (2017) · International Journal of Colorectal Disease · doi:10.1007/s00384-017-2800-1 · Cited by 133 · see citing works

Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis

Rumpold, H. F., Niedersüß‐Beke, D., Heiler, C., Falch, D., Wundsam, H., Metz-Gercek, S., Piringer, G., & Thaler, J. (2020) · BMC Cancer · doi:10.1186/s12885-020-07656-w · Cited by 119 · see citing works

Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer—central evaluation of FIRE-3

Modest, D. P., Denecke, T., Pratschke, J., Ricard, I., Lang, H., Bemelmans, M. H. A., Becker, T., Rentsch, M., Seehofer, D., Bruns, C. J., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.028 · Cited by 91 · see citing works

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer

Bennouna, J., Hiret, S., Bertaut, A., Bouché, O., Deplanque, G., Borel, C., François, É., Conroy, T., Ghiringhelli, F., Guetz, G. D., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4465 · Cited by 86 · see citing works

A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer

Ciombor, K. K., & Bekaii‐Saab, T. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0203 · Cited by 74 · see citing works

Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis

Baraniskin, A., Buchberger, B., Pox, C. P., Graeven, U., Holch, J. W., Schmiegel, W., & Heinemann, V. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.009 · Cited by 75 · see citing works

A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer

Heinemann, V., Rivera, F., O’Neil, B. H., Stintzing, S., Koukakis, R., Terwey, J.-H., & Douillard, J. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.07.019 · Cited by 59 · see citing works

Multiple treatment lines and prognosis in metastatic colorectal cancer patients

Carlomagno, C., Stefano, A. D., Rosanova, M., Falco, S. D., Attademo, L., Fiore, G., & Placido, S. D. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9748-7 · Cited by 58 · see citing works

Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis

Tabernero, J. M., Argilés, G., Sobrero, A. F., Borg, C., Ohtsu, A., Mayer, R. J., Vidot, L., Vera, S. R. M., & Cutsem, E. V. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000752 · Cited by 58 · see citing works

Precision medicine for metastatic colorectal cancer in clinical practice

Riedesser, J. E., Ebert, M. P. A., & Betge, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211072703 · Cited by 57 · see citing works

Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies

Aderka, D., Stintzing, S., & Heinemann, V. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30172-x · Cited by 55 · see citing works

Targeted therapy for metastatic colorectal cancer

Price, T. J., Tang, M., Gibbs, P., Haller, D. G., Peeters, M., Arnold, D., Segelov, E., Roy, A. C., Tebbutt, N. C., Pavlakis, N., et al. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1502664 · Cited by 54 · see citing works

Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)

Modest, D. P., Stintzing, S., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al‐Batran, S., Heintges, T., Kahl, C., Seipelt, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22396 · Cited by 49 · see citing works

Silencing LCN2 suppresses oral squamous cell carcinoma progression by reducing EGFR signal activation and recycling

Huang, Z., Rui, X., Chen, Y., Chen, Y., Chen, R., Liang, Y., Wang, Y., Yao, W., Xu, X., & Huang, Z. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02618-z · Cited by 49 · see citing works

Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer

Laurent‐Puig, P., Grisoni, M.-L., Heinemann, V., Liebaert, F., Neureiter, D., Jung, A., Montestruc, F., Gaston‐Mathé, Y., Thiébaut, R., & Stintzing, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1324 · Cited by 48 · see citing works

Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing

Kovaleva, V., Geißler, A.-L., Lutz, L., Fritsch, R., Makowiec, F., Wiesemann, S. D., Hopt, U. T., Passlick, B., Werner, M., & Laßmann, S. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0549-8 · Cited by 46 · see citing works

Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives

Holch, J. W., Stintzing, S., & Heinemann, V. (2016) · Visceral Medicine · doi:10.1159/000446052 · Cited by 44 · see citing works

Traditional Chinese Medicine Combined With Chemotherapy and Cetuximab or Bevacizumab for Metastatic Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Liu, N., Wu, C., Jia, R., Cai, G., Wang, Y., Zhou, L., Ji, Q., Sui, H. X., Zeng, P., Xiao, H., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00478 · Cited by 42 · see citing works

Role of Biologics in First-Line Treatment of Colorectal Cancer

Mahipal, A., & Grothey, A. F. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.018382 · Cited by 41 · see citing works

Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm

Ciracì, P., Studiale, V., Taravella, A., Antoniotti, C., & Cremolini, C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00965-0 · Cited by 42 · see citing works

Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer

Avallone, A., Piccirillo, M. C., Nasti, G., Rosati, G., Carlomagno, C., Gennaro, E. D., Romano, C., Tatangelo, F., Granata, V., Cassata, A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.18475 · Cited by 36 · see citing works

Immunotherapy as an Option for Cancer Treatment

Rusch, T., Bayry, J., Werner, J., Shevchenko, I., & Bazhin, A. V. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0491-5 · Cited by 33 · see citing works

The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside

Zaniboni, A., & Formica, V. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3032-8 · Cited by 32 · see citing works

Panitumumab‐based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials

Modest, D. P., Rivera, F., Bachet, J., de Braud, F., Pietrantonio, F., Koukakis, R., Demonty, G., & Douillard, J.-Y. (2019) · International Journal of Cancer · doi:10.1002/ijc.32110 · Cited by 32 · see citing works

Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019)

Ren, L., Zhu, D., Benson, A. B., Nordlinger, B., Koehne, C.-H., Delaney, C. P., Kerr, D. J., Lenz, H., Fan, J., Wang, J., et al. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.02.019 · Cited by 32 · see citing works

Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study

Grassadonia, A., Marino, P. D., Ficorella, C., Cortellini, A., Cannita, K., Parisi, A., Gamucci, T., Zoratto, F., Vici, P., Barba, M., et al. (2019) · Journal of Cancer · doi:10.7150/jca.34550 · Cited by 31 · see citing works

Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients

Cascinu, S., Rosati, G., Nasti, G., Lonardi, S., Zaniboni, A., Marchetti, P., Leone, F., Bilancia, D., Iaffaioli, R. V., Zagonel, V., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.029 · Cited by 30 · see citing works

Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies

Wang, N., Cao, Y., Si, C., Shao, P., Su, G., Wang, X., Bao, J., & Liu, Y. (2022) · Cancers · doi:10.3390/cancers14205160 · Cited by 27 · see citing works

Response to regorafenib at an initial dose of 120 mg as salvage therapy for metastatic colorectal cancer

Osawa, H. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1145 · Cited by 26 · see citing works

Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis

Helden, E. J. V., van Oordt, C. W. M. D. H., Heymans, M. W., Ket, J. C. F., van den Oord, R., & Verheul, H. M. W. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9668-y · Cited by 27 · see citing works

Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in KRAS wild‐type metastatic colorectal cancer patients: the ObservEr Study

Pinto, C., Fabio, F. D., Rosati, G., Lolli, I. R., Ruggeri, E. M., Ciuffreda, L., Ferrari, D., Re, G. L., Rosti, G., Tralongo, P., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.888 · Cited by 25 · see citing works

The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis

Cao, D., Xu, H., Xu, X., & Ge, W. (2017) · Oncotarget · doi:10.18632/oncotarget.19022 · Cited by 25 · see citing works

Efficacy‐effectiveness gaps in oncology: Looking beyond survival

Wilson, B. E., Hanna, T. P., & Booth, C. M. (2023) · Cancer · doi:10.1002/cncr.35075 · Cited by 25 · see citing works

Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas

Neuzillet, C., Rousseau, B., Kocher, H. M., Bourget, P., & Tournigand, C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.028 · Cited by 25 · see citing works

Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306

Modest, D. P., Heinemann, V., Folprecht, G., Denecke, T., Pratschke, J., Lang, H., Bemelmans, M. H. A., Becker, T., Rentsch, M., Seehofer, D., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08219-w · Cited by 23 · see citing works

New developments in targeted therapy for metastatic colorectal cancer

Wong, A. H. N., Ma, B. B. Y., & Lui, R. N.-S. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221148540 · Cited by 22 · see citing works

The role of cetuximab in converting initially unresectable colorectal cancer liver metastases for resection

Poston, G. J., Adam, R. A., Xu, J., Byrne, B., Esser, R., Malik, H., Wasan, H. S., & Xu, J. (2017) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.07.021 · Cited by 21 · see citing works

Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study

Parisi, A., Cortellini, A., Cannita, K., Venditti, O., Camarda, F., Calegari, M. A., Salvatore, L., Tortora, G., Rossini, D., Germani, M. M., et al. (2020) · Cancers · doi:10.3390/cancers12051259 · Cited by 21 · see citing works

Third-line treatment for metastatic colorectal cancer: anlotinib is superior to chemotherapy and similar to fruquintinib or regorafenib

Cheng, Y., DU, F. C., Fang, F., DUAN, Z. J., LEI, W., & SHI, K. G. (2020) · Neoplasma · doi:10.4149/neo_2020_191125n1212 · Cited by 21 · see citing works

Trying to Understand Differing Results of FIRE-3 and 80405: Does the First Treatment Matter More Than Others?

O’Neil, B. H., & Venook, A. P. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8495 · Cited by 21 · see citing works

Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO

Ciracì, P., Germani, M. M., Pietrantonio, F., Manca, P., Lonardi, S., Busico, A., Bergamo, F., Burgio, V., Mannavola, F., Donato, S. D., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.10.002 · Cited by 24 · see citing works

Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306)

Modest, D. P., Stintzing, S., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al‐Batran, S., Heintges, T., Lerchenmuller, C. A., Kahl, C., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30592 · Cited by 20 · see citing works

Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis

Chebib, R., Verlingue, L., Cozic, N., Faron, M., Burtin, P. C., Boige, V., Hollebecque, A., & Malka, D. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.07.004 · Cited by 20 · see citing works

Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies

Chen, D., Gu, K., & Wang, H. (2019) · Cancer Management and Research · doi:10.2147/cmar.s196170 · Cited by 20 · see citing works

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study

Pinto, C., Orlandi, A., Normanno, N., Maiello, E., Calegari, M. A., Antonuzzo, L., Bordonaro, R., Zampino, M. G., Pini, S., Bergamo, F., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01021 · Cited by 19 · see citing works

Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma

Peeters, M., Forget, F., Karthaus, M., Valladares‐Ayerbes, M., Zaniboni, A., Demonty, G., Guan, X., & Rivera, F. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000297 · Cited by 19 · see citing works

MicroRNA-940 restricts the expression of metastasis-associated gene MACC1 and enhances the antitumor effect of Anlotinib on colorectal cancer

Wang, Y., Zhao, M., Zhao, H., Cheng, S., Bai, R., & Song, M. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s195364 · Cited by 19 · see citing works

Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work

Harty, G. T., Jarrett, J., & Jofre‐Bonet, M. (2018) · Applied Health Economics and Health Policy · doi:10.1007/s40258-018-0395-5 · Cited by 18 · see citing works

Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)

Holch, J. W., Ricard, I., Stintzing, S., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Heintges, T., Kahl, C., Kullmann, F., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.001 · Cited by 18 · see citing works

Relevance of liver‐limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE‐3/AIO KRK0306 trial

Holch, J. W., Ricard, I., Stintzing, S., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al‐Batran, S., Heintges, T., Lerchenmuller, C. A., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.31114 · Cited by 16 · see citing works

Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements

Cann, C., LaPelusa, M. B., Cimino, S. K., & Eng, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1176950 · Cited by 16 · see citing works

Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer

Bai, L., Wang, F., Li, Z.-Z., Ren, C., Zhang, D., Zhao, Q., Lu, Y., Wang, D., Ju, H., Qiu, M., et al. (2016) · Medicine · doi:10.1097/md.0000000000004531 · Cited by 15 · see citing works

Prognostic value of metastatic pattern in colorectal cancer: a multicenter retrospective analysis in a real-life cohort

Rumpold, H. F., Kirchweger, P., Niedersüß‐Beke, D., Falch, D., Wundsam, H., Metz-Gercek, S., Piringer, G., & Thaler, J. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1837945 · Cited by 15 · see citing works

Highly sensitive detection of the PIK3CA H1047R mutation in colorectal cancer using a novel PCR-RFLP method

Li, W., Hu, T., Zhou, L., Feng, Y., Wang, Y., & Jin, F. (2016) · BMC Cancer · doi:10.1186/s12885-016-2493-9 · Cited by 15 · see citing works

Economic evaluation study (CHEER-compliant)

Zhou, J., Zhao, R., Wen, F., Zhang, P., Tang, R., Chen, H., Zhang, J., & Li, Q. (2016) · Medicine · doi:10.1097/md.0000000000003762 · Cited by 14 · see citing works

A Novel TGF-β-Related Signature for Predicting Prognosis, Tumor Microenvironment, and Therapeutic Response in Colorectal Cancer

Tao, B., Yi, C., Ma, Y., Li, Y., Zhang, B., Geng, Y., Chen, Z., Ma, X., & Chen, J. (2023) · Biochemical Genetics · doi:10.1007/s10528-023-10591-7 · Cited by 13 · see citing works

Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab

Taniguchi, H., Baba, Y., Sagiya, Y., Gotou, M., Nakamura, K., Sawada, H., Yamanaka, K., Sakakibara, Y., Mori, I., Hikichi, Y., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.04.006 · Cited by 13 · see citing works

Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild‐type KRAS exon 2 metastatic colorectal cancer

Hsu, H., Liu, Y., Wang, C., Chou, W., Hsu, Y., Chiang, J., Lin, Y., & Yang, T. (2019) · Cancer Medicine · doi:10.1002/cam4.2235 · Cited by 13 · see citing works

Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study

Marques, R. P., Godinho, A. R., Heudtlass, P., Pais, H. L., Quintela, A., & Martins, A. P. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03167-0 · Cited by 12 · see citing works

Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial

Avallone, A., & Budillon, A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1512 · Cited by 10 · see citing works

The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study

Tsai, H., Lin, C., Sung, Y.-C., Chen, S., Chen, L., Jiang, J., & Wang, J. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02366-z · Cited by 9 · see citing works

Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis

Kassouf, E., Tabchi, S., & Tehfe, M. A. (2016) · BioDrugs · doi:10.1007/s40259-016-0166-5 · Cited by 9 · see citing works

Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306

Froelich, M. F., Petersen, E. L., Heinemann, V., Nörenberg, D., Hesse, N., Gesenhues, A. B., Modest, D. P., Sommer, W. H., Hofmann, F. O., Stintzing, S., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.06.005 · Cited by 9 · see citing works

The best strategy for metastatic colorectal cancer (mCRC) patients in second-line treatment: A network meta-analysis

Xu, Z., Peng, X., Kong, Y., Cui, Y., Li, Y., & Guo, Y. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100455 · Cited by 9 · see citing works

Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis

Büchler, T., Chloupková, R., Poprach, A., Fiala, O., Kišš, I., Kopečková, K., Dušek, L., Veškrňová, V., Slavicek, L., Kohoutek, M., et al. (2018) · Cancer Management and Research · doi:10.2147/cmar.s183093 · Cited by 9 · see citing works

Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study

Fucà, G., Raimondi, A., Prisciandaro, M., Lonardi, S., Cremolini, C., Ratti, M., Clavarezza, M., Murialdo, R., Bianchi, A. S., Smiroldo, V., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyab012 · Cited by 9 · see citing works

Chemotherapy plus panitumumab/cetuximab versus chemotherapy plus bevacizumab in wild-type KRAS/RAS metastatic colorectal cancer: a meta-analysis

Zhang, C., Liu, L., Lv, Y., Li, J., Cao, C., Lu, J., Wang, S., Du, B., & Yang, X. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2147512 · Cited by 9 · see citing works

Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16

Yasui, H., Okita, Y., Nakamura, M., Sagawa, T., Watanabe, T., Kataoka, K., Manaka, D., Shiraishi, K., Akazawa, N., Okuno, T., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101636 · Cited by 8 · see citing works

Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306)

Modest, D. P., Ricard, I., Stintzing, S., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al-Batran, S.-E., Heintges, T., Kahl, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.030 · Cited by 8 · see citing works

Previous Bevacizumab and Efficacy of Later Anti–Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry

Burge, M., Semira, C., Lee, B., Lee, M., Kosmider, S., Wong, R., Shapiro, J. D., Ma, B. B. Y., Dean, A. P., Zimet, A. S., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.05.009 · Cited by 8 · see citing works

First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study

Liu, S., Jiang, C., Yang, L., Huang, J., Peng, R., Wang, X., He, W., Bai, L., Zhou, Y., Zhang, B., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-69230-5 · Cited by 8 · see citing works

Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial)

Stahler, A., Heinemann, V., Schuster, V., Heinrich, K., Kurreck, A., Gießen-Jung, C., von Weikersthal, L. F., Kaiser, F., Decker, T. W., Held, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.017 · Cited by 8 · see citing works

Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015

Price, T. J., Thavaneswaran, S., Burge, M., Segelov, E., Haller, D. G., Punt, C. J. A., Arnold, D., Karapetis, C. S., Tebbutt, N. C., Pavlakis, N., et al. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1170594 · Cited by 8 · see citing works

Impact of the individualization of the first‑line chemotherapy for advanced colorectal cancer based on collagen gel droplet‑embedded drug sensitivity test

Ochiai, T., Nishimura, K., Watanabe, T., Kitajima, M., Nakatani, A., Nagayasu, K., Naito, S., Sato, T., Kishine, K., Abe, Y., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.6960 · Cited by 8 · see citing works

The Predictive Effect of Primary Tumour Location in the Treatment of Metastatic Colorectal Cancer: A Canadian Consensus Statement

Abrahão, A. B. K., Karim, S., Colwell, B., Berry, S. R., & Biagi, J. J. (2017) · Current Oncology · doi:10.3747/co.24.3757 · Cited by 7 · see citing works

Combination adjuvant chemotherapy with targeted drugs for treatment of colorectal cancer: A network meta‐analysis

Wang, J., Luo, L., Wang, D., Guo, B., Li, J., Zhu, Y., & Tang, D. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26312 · Cited by 7 · see citing works

First-line treatment in metastatic colorectal cancer: Important or crucial?

Malka, D., Rotolo, F., & Boige, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.09.001 · Cited by 6 · see citing works

How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis

Galvano, A., Incorvaia, L., Badalamenti, G., Rizzo, S., Guarini, A. A., Cusenza, S., Castellana, L., Barraco, N., Calò, V., Cutaia, S., et al. (2019) · Cancers · doi:10.3390/cancers11081189 · Cited by 6 · see citing works

Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm

Antoniotti, C., Moretto, R., Rossini, D., Masi, G., Falcone, A., & Cremolini, C. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102135 · Cited by 5 · see citing works

Continuing Cetuximab vs Bevacizumab plus chemotherapy after first progression in wild-type KRAS, NRAS and BRAF V600E metastatic colorectal cancer: a randomized phase II trial

Li, D., Wang, F., Xu, S., Li, K., Meng, X., Huang, Y., Ma, N., Qiao, L., Kuang, G., Chen, J., et al. (2021) · Journal of Cancer · doi:10.7150/jca.60014 · Cited by 5 · see citing works

Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019

Lau, D. K., Burge, M., Roy, A. C., Chau, I., Haller, D. G., Shapiro, J. D., Peeters, M., Pavlakis, N., Karapetis, C. S., Tebbutt, N. C., et al. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1744439 · Cited by 5 · see citing works

Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial

Stahler, A., Karthaus, M., Fruehauf, S., Graeven, U., Müller, L., von Weikersthal, L. F., Caca, K., Goekkurt, E., Ballhausen, A., Sommerhäuser, G., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.103004 · Cited by 4 · see citing works

Efficacy of Liver Chemoembolization after Prior Cetuximab Monotherapy in Patients with Metastatic Colorectal Cancer

Szemitko, M., Golubinska-Szemitko, E., Sieńko, J., Falkowski, A., & Wiernicki, I. (2023) · Cancers · doi:10.3390/cancers15020541 · Cited by 4 · see citing works

Anti-EGFR Therapy for Left-Sided RAS Wild-type Colorectal Cancer—PARADIGM Shift

Robinson, H. R., & Lieu, C. H. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.1088 · Cited by 4 · see citing works

Harnessing epigenetics: Genome-wide DNA methylation assay for colorectal cancer therapy

Ishioka, C. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103062 · Cited by 4 · see citing works

Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment

Zhou, Y., Zhao, X., Lu, N., Cao, P., Leng, W.-B., Zhu, Q., Gou, H., Zhang, J., Li, X., & Qiu, M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111887 · Cited by 3 · see citing works

Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer

Urban, H., Maurer, G. D., Luger, A., Lorenz, N. I., Sauer, B., Stroh, C., Trojan, J., Mittelbronn, M. G. A., Steinbach, J., Harter, P. N., et al. (2020) · Cancers · doi:10.3390/cancers12103050 · Cited by 3 · see citing works

Optimal Sequence and Second-Line Systemic Treatment of Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Meta-Analysis

Wu, C., Hsu, C., Hsieh, M., Wang, J., Chang, M., Yang, C., & Su, Y. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215166 · Cited by 3 · see citing works

Best Sequence Therapy in RAS Wild-Type Metastatic Colorectal Cancer: Waiting for Randomized Crossover Clinical Trials

Nasti, G., & Ottaiano, A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.9086 · Cited by 3 · see citing works

Second-line treatment strategies for RAS wild-type colorectal cancer: A systematic review and Network Meta-analysis (NMA)

Nardo, P. D., Basile, D., Siciliano, A., Pelizzari, G., Corvaja, C., Buriolla, S., Ongaro, E., Grazia, D. M., Garattini, S. K., Foltran, L., et al. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.07.013 · Cited by 2 · see citing works

Physical insights guided rational design of anti-EGFR antibody to reverse the acquired resistance

Zhang, M., Fu, Y., Xie, T., Yang, Z., Zhang, D., & Zhou, R. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141304 · Cited by 2 · see citing works

Efficacy and safety of anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy for metastatic colorectal cancer in first-line and second-line therapies: a meta-analysis

Wang, Z., Wang, H., Ma, B., Gao, P., Song, Y., Xu, Q., Zhang, C., & Hu, Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s111240 · Cited by 2 · see citing works

2ND-Line Therapies After 1st-Line Therapy with Folfiri in Combination with Cetuximab or Bevacizumab in Patients with KRAS Wild-Type Metastatic Colorectal Cancer (MCRC)-Analysis of the AIO KRK 0306 (FIRE 3)- Trial

Modest, D., Stintzing, S., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling-Kaiser, U., al Batran, S.-E., Heintges, T., Lerchenmuller, C. A., Kahl, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu193.18 · Cited by 3 · see citing works

Sequence of drugs—more important than drug exposure?

(2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.149 · Cited by 1 · see citing works

Second-line therapies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK0306 (FIRE 3) trial.

Modest, D. P., Stintzing, S., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al‐Batran, S., Heintges, T., Lerchenmuller, C. A., Kahl, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.3558 · Cited by 8 · see citing works

Clinical relevance of subsequent treatment procedures on overall survival in FIRE-3/AIO KRK0306 (FOLFIRI plus cetuximab [arm A] or bevacizumab [arm B]) in patients with KRAS wild-type metastatic colorectal cancer

Modest, D. P., Stintzing, S., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmuller, C. A., Kahl, C., et al. (2016)

Time-course evaluation of survival and treatment in FIRE-3 (AIO KRK0306, first-line therapy of KRAS wild-type metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab).

Modest, D. P., Stintzing, S., von Weikersthal, L. F., Sobrero, A. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al‐Batran, S., Heintges, T., Seipelt, G., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.617